1. Home
  2. MIRM vs PGNY Comparison

MIRM vs PGNY Comparison

Compare MIRM & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$65.07

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Logo Progyny Inc.

PGNY

Progyny Inc.

HOLD

Current Price

$26.65

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
PGNY
Founded
2018
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
2.1B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
MIRM
PGNY
Price
$65.07
$26.65
Analyst Decision
Strong Buy
Buy
Analyst Count
11
9
Target Price
$87.55
$27.44
AVG Volume (30 Days)
545.4K
1.4M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
2.96
EPS
N/A
0.62
Revenue
$471,794,000.00
$1,268,689,000.00
Revenue This Year
$53.78
$11.55
Revenue Next Year
$19.91
$9.52
P/E Ratio
N/A
$43.16
Revenue Growth
53.66
11.41
52 Week Low
$36.88
$13.86
52 Week High
$78.55
$27.51

Technical Indicators

Market Signals
Indicator
MIRM
PGNY
Relative Strength Index (RSI) 36.47 65.74
Support Level $63.66 $23.78
Resistance Level $66.77 $25.27
Average True Range (ATR) 2.99 0.86
MACD -0.66 -0.09
Stochastic Oscillator 13.68 76.86

Price Performance

Historical Comparison
MIRM
PGNY

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About PGNY Progyny Inc.

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

Share on Social Networks: